epothilone B   Click here for help

GtoPdb Ligand ID: 13600

Synonyms: EPO-906 | EPO906 | patupilone
PDB Ligand
Compound class: Synthetic organic
Comment: Epothilone B is a macrolide from plant (Sorangium cellulosum, a soil-dwelling Gram-negative myxobacterium), Aspergillus fumigatus [3] and insect (Apis cerana, Asiatic honey bee) sources. It mimics the microtubule binding activity of taxoid drugs such as paclitaxel (taxol) [1,5], but is active in [4] paclitaxel resistant cells. It acts to stabilise microtubules, which induces mitotic arrest and cell death.

epothilone B is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 2
Topological polar surface area 134.02
Molecular weight 507.68
XLogP 2.14
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C[C@H]1CCC[C@]2(C)[C@H](C[C@@H](/C(=C/C3=CSC(=N3)C)/C)OC(=O)C[C@@H](C(C)(C)C(=O)[C@H](C)[C@H]1O)O)O2
Isomeric SMILES C[C@H]1CCC[C@@]2([C@@H](O2)C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)C)/C)C
InChI InChI=1S/C27H41NO6S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)33-23(30)13-21(29)26(5,6)25(32)17(3)24(15)31/h11,14-15,17,20-22,24,29,31H,8-10,12-13H2,1-7H3/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1
InChI Key QXRSDHAAWVKZLJ-PVYNADRNSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
As EPO906, this compound was investigated for anti-tumour efficacy.
A semi-synthetic analogue of epothilone B, known as ixabepilone or BMS 247550, was also progressed to clinical trials in advanced cancers.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00715013 Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma Phase 1/Phase 2 Interventional University of Zurich
NCT00969046 Dose-Escalation Study in Advanced Colon Cancer Patients Phase 1 Interventional Novartis
NCT00262990 Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer Phase 3 Interventional Novartis